NLM Logo

Tumor Lysis Syndrome MeSH Descriptor Data 2023


MeSH Heading
Tumor Lysis Syndrome
Tree Number(s)
C15.604.515.880
C20.683.515.950
Unique ID
D015275
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D015275
Annotation
lymphoproliferative disord caused by anticancer drugs; coord IM with /‌etiol (not /‌chem ind) + anticancer drug /‌adv eff (IM) + required neopl coords /‌drug ther (IM or NIM) if pertinent
Scope Note
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
Entry Term(s)
Tumour Lysis Syndrome
Previous Indexing
Antineoplastic Agents, Combined/adverse effects/therapeutic use (1980-1988)
Antineoplastic Agents/therapeutic use (1984-1988)
Burkitt's Lymphoma/complications (1980-1988)
See Also
Tumor Necrosis Factor-alpha
Public MeSH Note
89
History Note
89
Date Established
1989/01/01
Date of Entry
1988/05/19
Revision Date
2004/07/20
Tumor Lysis Syndrome Preferred
page delivered in 0.151s